RIO DE JANEIRO — The addition of daratumumab to lenalidomide maintenance therapy following autologous stem cell transplant (ASCT) significantly improves rates of achieving minimal residual disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback